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Infants and very young children are poor responders to polysaccharide anti-
gens (1-4) and fail to make protective antibody responses to a number of
polysaccharide-containing vaccines including the 23-valentpneumococcal vaccine
(2, 5) currently used to immunize adults (6) . One way to attempt immunization
of children againstencapsulated bacteria is to modify thecapsular polysaccharides
so that they will be antigenic in children . Another is to identify bacterial proteins
that can elicit sufficiently protective responses . The studies described in this
paper are based on our recent demonstration that two mAbs reactive with a
pneumococcal surface protein A (PspA)' present on the nonencapsulated pneu-
mococcal strain R36A, and on some encapsulated strains (7), can protect mice
from fatal pneumococcal infection with certain type 3 and type 2 strains (8).
Whether or not such pneumococcal proteins can elicit protective responses in
animalsorhumans, and whether or not these proteins play a role in pneumococcal
virulence, has not previously been established.
The ability of pneumococcal surface components, in addition to the capsule,
to elicit protective immune responses could account for the early observations
that the most protective horse antipneumococcal sera were made against highly
virulent pneumococci (9) and that the presence of anticapsular antibody in the
sera did not necessarily mean that they wouldbe highly protective (10) . Although
there were a number of early reports (11-15) of protective antibodies directed
against antigens other than the capsular polysaccharide, the subject of antigenic
pneumococcal proteins ceased to be a major topic o£ investigation after Avery
and Goebel demonstrated (16) in 1933 that the protective properties of an
immune serum from a horse could be completely removed by absorption with
isolated type 1 polysaccharide . Protective antibodies to protein components of
the pneumococcus may have been difficult to detect, in part because antibodies
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TABLE I
Bacterial Strains
* R36A is a nonencapsulated derivative ofthe virulent type 2 strain D39.
RxI is a highly transformable derivative of R36A.
to the cell wall and capsular polysaccharides may predominate in the immune
response to live and killed whole pneumococci (8) and because anticapsular
antibodies are probably more protective than antibodies to pneumococcal pro-
teins.
Injection of intact cells of the nonencapsulated strain R36A can elicit protec-
tion against certain encapsulated Streptococcus pneumoniae in xid mice (17) . It
seemed likely that this protection was due to antiprotein antibodies because the
immunogen used did not contain capsular polysaccharide and because xid mice
fail to make antibodies to polysaccharides including the teichoic acids of pneu-
mococcal cell walls (18).
To facilitate subsequent investigation of the functional and structural proper-
ties of PspA, including its ability to elicit protective immune responses, we have
constructed mutants of S. pneumoniae strain Rx1, a variant of R36A (19), which
fail to express this cell surface protein . From one of these mutants we have
cloned a 550 by DNA fragment that appears to be part of the PspA structural
gene. In this report we describe the generation of this cloned fragment and
studies in which the plasmid containing the cloned fragment was used to produce
congenic PspA- pneumococcal strains that were used to evaluate the biological
effects of PspA.
Materials and Methods
Bacterial Strains.
￿
The strains used in this study are listed in Table 1.
Growth and Maintenance ofStrains.
￿
All strains were maintained as 10% glycerol frozen
stocks at -80°C. Pneumococcal cultures were grown according to procedures routinely
used in our lab (24) and were harvested by centrifugation (4,000 g, 10 min). Their
concentrations were confirmed by plating on blood agar. Escherichia coli cultures were
grown in LB medium (25) unless otherwise specified.
Mice.
￿
CBA/N mice were obtained from Dominion Laboratories, Dublin, VA. (CBA/N
Strain Relevant genotype/phenotype Reference
S. pneumoniae:
R36A* PspA+ 8,19
Rxl t hex, PspA+ 20
DP1617 ery-2, str-1,fus, sul-d, nov-1, stg 21
WG44.1 ery-2 PspA- This paper
WG44.2 ery-2, PspA- This paper
WG44.3 ery-2, PspA- This paper
D39 PspA+ 19
JY53 ery-2, PspA- This paper
JY54 ery-2, PspA- This paper
WU2 PspA+ 22
Escherichia coli
DH1 F-, endA1, hsdR17, (rk, mk+), supE44, thi-1, a-, recA1, 23
gyrA96, re1AIMcDANIEL ET AL .
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X DBA/2)F, mice were raised by crossing CBA/N females with DBA/2 males obtained
from The Jackson Laboratory, Bar Harbor, ME .
Bacterial Transformation.
￿
Transformations of pneumococcal strain Rxl and mutants
derived from it were carried out by established procedures (26) . Cells weregrown to high
competence in the complete transformation medium (CTM) of Smith et al . (27) . Alter-
natively, Todd-Hewitt broth containing 0 .5% yeast extract was substituted as the basal
medium then supplemented after autoclaving to 1 mM CaC1 2 and 2 mg/ml of BSA .
Similar transformation frequencies of Rx 1 were observed with both media . Competent
pneumococci were produced by growing a culture of recipient pneumococci to a density
of 3 X 10 8 cells/ml in basal medium, diluting 100-fold into competence medium, and
removing a sample of cells at 10-min intervals over a period of about 200 min . Aliquots
of the cells removed at each time point were stored frozen in 10% glycerol at -80°C . To
determine the time point at which competent cells were obtained, cells from each time
point were used for transformation as described below . From then on, transformation
studies were done with cells grown under the same conditions to the optimum time point,
made 10% in glycerol, and stored frozen at -80°C .
For transformation, cultures were thawed at 37°C and added to 0.1 volume of DNA
(usually at a concentration of 1 gg/ml) at the same temperature . The cells were then
incubated for 1 h to allow phenotypic expression . Dilutions were then made and plated
on blood agar containing the appropriate antibiotic . Virulent, encapsulated pneumococci
were transformed by using competent, heat-killed broth cultures of Rxl to induce
competence (28) .
E. coli strain DHI at ^-10' CFU/ml was transformed with <10 jl containing -0.2 ug
of plasmid DNA by the method ofHanahan (23) .
Insertion Inactivation Mutagenesis . Extracted pneumococcal chromosomal DNA was
digested with Hind III, Barn HI, or Sau 3A according to the manufacturer's (Boehringer
Mannheim Biochemicals, Indianapolis, IN) instructions and ligated to the appropriate
digest of pVA891 (29) that can replicate autonomously in E. coli but not streptococci .
The product of this ligation reaction was used to transform strain Rx1 at about 20 ng
DNA/ml of culture (30) . A portion of each culture was plated to score the number of
Em' transformants . To select for Em' transformants, the rest of the culture was diluted
100-fold into growth medium containing 2 wg/ml erythromycin and was grown to 5 X
108 bacteria per ml . The cultures were supplemented to 10% glycerol and stored frozen
at -80'C . Individual colonies were tested for inactivation of genes coding for surface
antigens detected by our mAbs by the colony immunoblot procedure described below .
Three isolates that did not express PspA were designated WG44 .1, WG44.2, and
WG44.3 . The remainder of the isolates screened still produced PspA. Five of these,
designated WG44.5, WG44.6, WG44.7, WG44.9, and WG44.12, were used as donors
for the introduction by chromosomal transformation of pVA891 into non-PspA portions
of the D39 chromosome . D39 isolates obtained all were Em' and still produced PspA .
These isolates have been identified as LC 10.1, LC 10.2, LC 10 .3, LC 10.5, and LC 10 .8 .
Colony Blot Procedure for the Detection of PspA' mutants of Rxl .
￿
Pneumococci were
plated onto blood agar plates containing 2 wg/ml of erythromycin at about 100 CFU/plate
and were incubated overnight at 37'C in a candle jar . Individual colonies were blotted
onto a sterile nitrocellulose membrane by placing the membrane over the colonies on the
surface of the agar and then gently lifting it off. The membrane was incubated for 1 h at
room temperature with 1% BSA in PBS and transferred to a 10% solution ofmAb tissue
culture supernatant in 0.05% Tween 20 in PBS (PBST) for 2 h at room temperature on
a rocking platform . The membrane was washed three times for 5 min each with PBST,
and then incubated for 2 h at room temperature with isotype-specific affinity-purified
goat anti-mouse alkaline phosphatase-conjugated antibody (0 .2 /+g/ml) diluted in PBST .
As a control, all new lots ofgoat immune sera were tested for reactivity with pneumococcal
antigens . The membrane was again washed with PBST, and the alkaline phosphatase
conjugates were visualized by placing the membrane in 0.5 mg/ml of 5-bromo-4-chloro-
3-indolyl phosphate (BCIP) (Sigma Chemical Co ., St . Louis, MO) in I M Tris, pH 8.8, on384
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a rocking platform (31, 32) . The development of blue spots (i.e ., colonies) was stopped by
rinsingthe membrane several times with deionized water .
Immunostaining ofElectroblotted SDS Gels (Immunoblotting) .
￿
Electrophoresed PspA was
visualized by standard immunoblotting techniques . Crude lysates were prepared by
detergent-augmented autolysis as described previously (8) . We used a modification of the
method described by Lacks and Neuberger (33) for autoplast formation to produce a cell
wall extract(CWE)ofpneumococcal strains (7) . Pneumococci were grown to ^-109 cells/ml
in 500 ml of Todd-Hewitt broth supplemented with 0.5% yeast extract. Cells were
harvested by centrifugation, washed once with PBS, and resuspended in 3 ml of PBS
containing 20% sucrose and 0.05 M M9Cl2 . After 24 h at room temperature, the
suspension was centrifuged (4000 g, 10 min, 4°C) to remove the protoplasts . The
supernatant was dialyzed against three changes ofPBS at 4°C and centrifuged at 10,000
g for 10 min to remove insoluble material . The amount of protein in the CWE was
determined by a microassay (Bio-Rad Laboratories, Richmond, CA) . The CWE was
aliquoted and stored at -20 °C until use .
SDS-PAGE was carried out on unlabeled CWE using 20 ul of cell material (1 jug/j,l
total proteins) added to 20 Al of SDS-PAGE sample buffer . This was placed in a boiling
water bath for 5 min before loading in the well of a 5-12% gradient gel (34) . After
electrophoresis, the proteins were transferred to nitrocellulose (Millipore, Bedford, MA)
using a Trans-Blot apparatus (Bio-Rad Laboratories) with the transfer buffer described
by Burnette (35) . Aftertransfer of the proteins, themembrane was processed as described
in the colony blot assay .
Preparation of 32P-labeled DNA probe.
￿
Plasmid DNA containing the pneumococcal
insert, pKSD300, was purified by the method of Birnboim and Doly (36) . The purified
plasmid DNA was digested with Sau 3A to generate a unique pneumococcal fragment,
which was separated from the vector DNA on a 0.7% agarose gel . The pneumococcal
fragment was isolated by the method of Dretzen et al . (37) . The purified DNA fragment
was 32P-labeled by nick translation synthesis (38) using a commercially available kit
(Amersham Corp ., Arlington Heights, IL) .
Southern Blot Analysis. High molecular weight pneumococcal genomic DNA was
prepared by resuspending 109 bacteria in 0.5 ml of lysis buffer (0.1% sodium deoxycholate,
0.01% SDS, and 0.15 M sodium citrate) for 60 min at 65 °C. Proteinase K was added to
100 wg/ml, and the suspension was incubated overnight at 37°C . It was then extracted
twice with phenol, once with CHC13/isoamyl alcohol (24:1), and dialyzed overnight at 4°C
against Tris/EDTA (10mM Tris, pH 8.0, and 1 mM EDTA) . RNase was added to 100
,ug/ml, and the suspension was incubated for 2 h at 37°C followed by a second 2-h
incubation in the presence of 10 wg/ml of proteinase K. The DNA was extracted twice
with phenol and once with CHCl 3/isoamyl alcohol, and was dialysed extensively against
Tris/EDTAatVC . C.
For Southern analysis, the pneumococcal genomic DNA was digested with various
enzymes, the fragments were separated by agarose gel electrophoresis, and were trans-
ferred to a nitrocellulose membrane . Hybridization was at 42°C in 50% formamide in
sealed plastic bags . Membranes were washed as stringently as possible, and then autora-
diographed on Kodak XA film using intensifying screens (25) .
Colony hybridization was carried out under similar conditions using pneumococcal
strains grown directly on nitrocellulose membranes laid on blood agar plates . After lysis,
denaturation, and neutralization, the DNA was bound to the membrane by baking at
80°C for 2 h under a vacuum (25) .
Mouse Immunization Studies .
￿
We immunized xid mice with two weekly intravenous
injections of 2 X 103 heat-killed Rxl (PspA+) or WG44 .1 (PspA-) . After a 6-d rest, the
mice were injected with 25 or 100 CFU of WU2, type 3, intravenously in 0.2 ml of
Ringer's lactate (the LD50 for WU2 in xid mice is 1-2 CFU) . Mice were observed and
deaths were recorded for a 10-d period after inoculation .
Blood Clearance Assays .
￿
The rate of removal of pneumococci from the blood was
determined using previously described procedures (24) . Mice were challenged intrave-
nously with mixed cultures containing equal numbers of PspA+ (D39) and PspA- (JY53McDANIEL ET AL .
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FIGURE 1 .
￿
Immunoblot of pneumococcal lysates following SDS electrophoresis . Lysates from
wild type strain Rx1 (lane 1) and insertionally inactivated mutants WG44 .1, WG44 .2, and
WG44.3 (lanes 2-4) were run on SDS gels and immunoblotted with the anti-PspA antibody
Xi164. Molecular mass (kD) markers are shown .
or JY54) pneumococci . The total number of pneumococci injected was ^-105 . Blood
samples were collected from the retroorbital plexus at the indicated times in calibrated
heparinized capillary pipettes . The samples were serially diluted in Ringer's lactate and
plated on blood agar to determine the total number of viable pneumococci in the blood
or on blood agar containing 5 gg/ml of erythromycin to determine the number of
mutants .
Results
Isolation of Insertionally Inactivated PspA mutants.
￿
We used the colony blot
procedure to screen for PspA mutants of Rx 1 that had occurred as a result of
insertion mutagenesis after transformation with ligation mixtures of the plasmid
pVA891 and random restriction fragments of Rx1 chromosomal DNA. Only
one of three chromosomal libraries yielded mutants that failed to react with anti-
PspA antibody Xi64 . This was the library constructed using Sau 3A endonucle-
ase . We identified three mutants from this libraryand designated them WG44.1 .
WG44.2, and WG44.3 . The frequency of mutation observed was ^-1 per 380
Emr colonies .
PspA was not detected by immunoblot analysis of lysates of the three mutants
(Fig . 1), indicating that the PspA- phenotype was not due merely to a failure to
export the protein to the surface .
We used the colony blot assay to test the ability of our anti-PspA mAbs Xi64,
Xi69, Xi126, and HPR36A to bind to the mutants. Although our previous data
had suggested that our four anti-PspA mAbs reacted with different epitopes (8),
it appeared that they all detected the same molecule (7) . This interpretation was
consistent with our colony blot results since all four antibodies reacted with the
wild-type Rx1 pneumococci, but none of them reacted with any of the mutants .
Cloning of a Pneumococcal Fragment from the Inactivated Gene.
￿
By extracting
DNA from the mutants, and using this DNA to transformE . coli, we were able
to isolate a single clone that carried a fragment of about 550 bp . When this
chimeric plasmid, derived from pVA891 and designated pKSD300, was used to
transform wild-type Rxl, 32 of 32 of the resulting transformants failed to
produce PspA . This indicated that we had cloned a fragment that carried
homology with a gene necessary for the production of PspA .
Southern Blot Analysis.
￿
We examined the ability of our cloned fragment to
bind restriction enzyme fragments of chromosomal DNA isolated from PspA-386
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FIGURE 2 .
￿
Southern blot analysis of RxI chromosomal DNA digested with Bam HI (lane 1),
Hind III (lane 2), or Eco RI (lane 3) . After transfer to a nitrocellulose membrane, the digested
DNA was hybridized with the s4P-labeled PspA-specific probe isolated from pKSD300.
producing wild-type cells . 12P-labeled probe isolated from pKSD300 hybridized
to unique fragments of Rxl chromosomal DNA that had been digested with
Bam HI, Hind III, or Eco RI and electrophoresed in agarose (Fig. 2) .
Colony Hybridization Analysis.
￿
To further confirm the specificity of our DNA
probe, we did colony hybridization experiments in which the 12P-labeled probe
from pKSD300 was tested for its abilityto bind theDNA from 102 pneumococcal
isolates representing 21 serotypes . These isolates were also tested for their ability
to react with mAbs Xi64 and Xi126 in a colony blot assay. In agreement with
our previous study (7), the reactivity of the mAbs with the isolates was relatively
independent of their capsular serotypes (data not shown) . The reactivity of the
probe with the isolates was also relatively independent oftheir capsular serotypes
(Table II, footnote) .
When the reactivity of the anti-PspA antibodies with the isolates was compared
with the reactivity of the probe with the isolates, it was observed that although
there was not a one to one correlation in the ability to react with the antibody
and the DNA probe, 18 of the 25 isolates that produced PspA as detected by
either Xi64 or Xi126, did react with the probe and only 3 of 77 isolates that
failed to react with either antibody reacted with the probe (Table II) . These
results indicated that our probe reacted preferentially with pneumococcal strains
that produce a PspA that is immunochemically similar to that of strain Rx 1 . We
also tested five group A and five group B streptococcal isolates in these assays .
None of these bacteria reacted with either of our antibodies or the DNA probe .
Transformation and Growth Rate ofPspA Mutants.
￿
We examined the effect ofMcDANIEL ET AL.
TABLE II
Pattern ofReactivity ofAnti-PspA Antibody and PspA Probe with
Pneumococcal Isolates
TABLE III
* The reactivity ofthe probe with strains of the 21 capsular serotypes was
as follows : type 1, 0/3 (isolates reactive with the probe per isolates of
serotype tested) ; type 2, 3/4 ; type 3, 4/11 ; type 4, 0/10 ; type 5, 1/1 ;
type 6, 3/14 ; type 7,'1/7 ; type 8, 0/2 ; type 9, 2/8 ; type 10, 0/4 ; type
11, 0/1 ; type 12, 1/1 ; type 14, 2/7 ; type 16, 0/3 ; type 18, 0/5 ; type 19,
1/8; type 21, 0/2 ; type 23, 1/6 ; type 27, 0/1 ; type 31, 1/3 ; and type 33,
1/1.
Transformation ofS . pneumoniae with a Chromosomal Str' Marker
* The frequency of transformants per viable cells. These data represent
averages obtained from four separate experiments, each of which pro-
vided results indicating that PspA* pneumococci transform about 4-10
times more efficiently than PspA- pneumococci . In each of the four
experiments the PspA+ andPspA' cell lines used were grown to identify
cells in the stage of growth showing maximal transformation efficiency.
Thedata given are basedon values obtained using cellsfrom each strain
that were harvested on the time point of highest transformation effi-
ciency of that strain in that particular experiment.
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this mutation on the ability of the mutants to undergo genetic transformation
with a chromosomal Str' marker . As controls we included strains WG44.7,
WG44.9, and WG44.13, three independently obtained derivatives of Rx1 that
expressed PspA but contained pVA891 in some non-pspA portion of their
chromosome . As can be seen in Table III, the presence of PspA is not essential
for transformation since the PspA- strains could still be readily transformed . We
did observe a reproducible, but slightly higher frequency of transformation of
Number of isolates
Xi64
Reactivity with:*
Xi126 550 by PspA
probe
8 + + +
7 + - +
3 - + +
3 - - +
1 + + -
1 + - -
5 - + -
74
Recipient strain Chromosomal
pVA891
PspA
expression
Transformation
frequency*
RxI - + 1/100
WG44.1 + - 1/970
WG44.2 + - 1/940
WG44.3 + - 1/890
WG44.7 + + 1/230
WG44.9 + + 1/230
WG44.13 + + 1/210388 A PNEUMOCOCCAL IMMUNOGEN AND VIRULENCE FACTOR
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FIGURE 3 .
￿
Growth rate of RxI (PspA+) and WG44 .1 (PspA-) in Todd-Hewitt broth supple-
mented with 0.5% yeast extract. Exponentially growing bacteria were diluted to equivalent
cell densities of 5 X 10 4/ml in prewarmed medium . Viable cell counts were determined by
making 10-fold serial dilutions, platingon blood agar plates, and incubating overnight at 37°C
in a candlejar .
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FIGURE 4 .
￿
Survival curve of CBA/N (xid) mice protected from type 3 S . pneumoniae after
immunization with Rxl. Mice were given two weekly injections of 2 X 108 heat-killed RxI or
WG44 .1 . 6 dafter the last injection, they were challenged with either 102 or 10 9 CFU oftype
3 strain WU2 pneumococci . Each line represents a total of 12 mice from two experiments .
Similar results (not shown) were observed when mice were immunized with strain LM34
(PspA-), which was obtained by transforming Rx 1 with pKSD300 .
PspA+ vs . PspA- strains . This finding suggests that the presence ofPspA on the
bacterial surface may have some effect on the frequency of transformation .
Using one of the mutants, we also observed that a lack of PspA had no effect
on the rate ofgrowth of these bacteria in a complex medium (Fig . 3) .
Immune Response of xid Mice to PspA .
￿
To evaluate the protective potential of
PspA, we immunized xid mice with two weekly intravenous injections of Rx 1
(PspA+) or WG44 .1 (PspA-), rested them, and infected them with WU2, type 3,
pneumococci . We were able to avoid complicating factors caused by antibodies
to the PC determinant of the teichoic acids and to the capsule in part by using
xid mice that cannot produce antibodies to most polysaccharides including both
of these antigens (18) . Potential problems with anticapsular antibodies were
doubly eliminated since the immunizing strains were nonencapsulated derivatives
of a type 2 strain . The survival of the mice is depicted in Fig. 4 . These resultsMcDANIEL ET AL .
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TABLE IV
Mortality ofMice Infected with PspA' and PspA - S . pneumoniae
PspA' is D39 . Data from experiments with both JY53 andJY54 were pooled to obtain the PspA-
data . There were no statistically significant differences between the data obtained with JY53 and
JY54 .
* Deaths were recorded at intervals of every 1-3 h during the experiment. Mice alive at 10 d were
arbitrarily assigned a time of death of 240hfor the calculations of the reciprocal mean andpvalue .
$ The median days to death was calculated as the reciprocal mean and expressed with the range of
standard error .
4p values ; calculated by the two sample rank test from the time of death of the individual mice in
each group .
indicate that the presence ofPspAon pneumococci can elicit protective immunity
against pneumococcal infection .
Relative Pathogenesis ofD39 and D39 Mutants Lacking PspA .
￿
To analyze its
effect on virulence, the PspA- mutation was introduced into the type 2 strain
D39 by transformation with pKSD300 . Seven ofseven isolates tested were PspA-,
as determined by the colony blot assay, and two of these,JY53 andJY54, were
chosen for the virulence studies . Although the PspA- mutants, JY53 andJY54,
could still cause fatal infection of both xid and non-xid mice, the median time to
death of mice infected with them was significantly later than that of mice infected
with D39 (Table IV) . The reduction in the virulence resulting from the loss of
PspA was more apparent in blood-clearance studies . The number of mutant
bacteria remaining in the blood 1 h after infection was reduced ^" I O-fold when
compared with the parent D39 strain in a mixed infection (Fig . 5) . After this
first hour, no further decreases occurred and the ratios of PspA- to PspA+
isolates remained essentially unchanged .
Control strains were prepared for the blood-clearance studies that carried the
pVA891 plasmid in their chromosome but still expressed PspA . These were
constructed by transforming D39 with chromosomal DNA from individual
pneumococci obtained from the Rxl library of random pVA891 inserts . Inde-
pendently transformed D39 colonies, detected by screening for erythromycin
resistance, were used as sources ofDNA to backcross the chromosomally inserted
pVA891s once more onto the D39 background . Using these strains, it was
possible to show that the rapid early blood clearance of JY53 and JY54 was
because of their lack of PspA and not because of some effect of simply carrying
pVA891 in their chromosomes . Five D39 strains carrying pVA891 but still
expressing PspA showed exactly the same blood-clearance patterns as D39 (Table
V) .
Discussion
We have isolated mutants ofS . pneumoniae that fail to produce PspA and have
cloned a 550 by fragment ofa gene required for its production into the plasmid
Mice Intravenous
challenge
Num-
bmrcof
Median hours to
death*4
Alive at
20 d
PspA+ vs .
PspA-*4
(CBA/N x DBA/2)F, 300 PspA' 10 41(37-46) 10
males (xid) 300 PspA' 17 54(48-60) 12.5 <0.03
(CBA/N x DBA/2)F, 106 PspA' 8 58(46-78) 25
females (non-xid) 106 PspA- 16 133(111-162) 56 <0 .06390
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TABLE V
. PspA
JY53
0 2 4 0 2 4
hours
FIGURE 5. Comparison of blood clearance of PspA' (D39) vs. PspA- (JY53 or JY54)
pneumococci. Both xid ([CBA/N X BALB/c]F, males, left panels) and normal ([CBA/N X
BALB/cJF1 females, right panels) mice were infected intravenously with mixed cultures
containing approximately equal numbers of D39 andJY53 (panels A, B, and E) or D39 and
JY54 (panels C, D, and F). Thenumber ofbacteria wasdetermined by bleeding at 1 min(time
0), 1 h, and 4 h and plating for total CFU (i.e., D39 plus mutant) and for Eryr CFU (mutant
only). A-D show the numbers of D39 and the numbers of mutant recovered from a single
mouse in a typical experiment. E and F indicate the ratios ofJY53 andJY54, respectively, to
D39. These ratios were obtained from the averages of six and five mice, respectively.
The Effect ofRandom pVA891 Insertions on the Virulence ofD39
* Mice were injected intravenously with ^-106 pneumococci in 0.1 ml and
bled at I minand 1 hafter inoculation. Data representaverages obtained
from two mice. In all cases the duplicate values were within 2.7-fold of
each other, except for the I h data forJY53, which was 2 x 103 and 8.5
X 10' CFU per ml, and the I h data for LC10.3, which was 1 .1 x 105
and4.0 x 105 CFU/ml.
t LCIOA, LC10.2, LC10.3, LC10.5, and LCI0.8 were made by trans-
forming D39 with Rxl derivatives WG44.5, WG44.6, WG44 .7,
WG44.9, and WG44.12 that carry pVA891 as random inserts in their
DNA. Transformants were selected as Em`colonies.
Strain Source of
pVA891 PspA
CFU/ml
I min
ofblood*
1 h
D39 - + 1 .8 x 105 1.8 x 105
JY53 pSD300 - 4.4 x 105 5.1 x 103
LC 10.1t WG44.5 + 1 .4 x 106 6.0 x 105
LCI0.2 WG44.6 + 8 .8 x 105 2.8 x 105
LC10.3 WG44.7 + 1 .5 x 106 7.5 x 105
LC10.5 WG44.9 + 2 .2 x 105 2.7 x 105
LC10.8 WG44.12 + 3.8 x 105 1 .0 x 105McDANIEL ET AL .
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pVA891 . When the recombinant plasmid, pKSD300 is introduced by transfor-
mation into Rx1 or into encapsulated pneumococcal strains, it insertionally
inactivates the pspA gene and totally blocks the production ofPspA .
When we examined the pattern of reactivity of a "P-DNA probe made from
the 550 by fragment with a panel of 102 pneumococcal strains, we saw that the
probe reacted with most, but not all of the isolates that reacted with the anti-
PspA antibodies . The simplest interpretation of this data is that the probe detects
a portion of thepspA structural gene that is different from those portions coding
for the antigenic determinants detected by our antibodies . The possibility that
our cloned gene is a fragment of a regulatory gene required for PspA production
seems unlikely since some of the isolates made detectable PspA but did not react
with the probe .
If the probe were reacting with a regulatory gene, the existence of those
strains could have only occurred if those particular strains did not need the
regulatory gene, or if both the regulatory gene and the structural gene were
polymorphic . If the latter was the case, it seems unlikely that the PspA protein
variant detected by the antibodies and the regulatory gene variant detected by
the probe would cosegregate in such a high frequency of randomly chosen
pneumococcal isolates . Likewise, if the regulatory gene were not needed in all
pneumococcal strains that express PspA, it is surprising that the ability to make
PspA in the absence of this gene would not show a more random association
with the production of the PspA variant detected by our antibodies .
Ifwe assume that the pspA probe does in fact detect a portion of the structural
gene, then the data in Table III indicate that this gene must be highly poly-
morphic among different pneumococcal isolates . Among the 28 strains that
reacted with either the anti-PspA antibodies or the pspA probe, all seven of the
possible reactivity patterns of antibody and probe were observed . This high
polymorphism of PspA would be consistent with a surface molecule that was
under selective pressure from immune responses to be expressed in as many
different serotypes as possible .
It seems likely that many of the 74 strains that failed to react with either the
antibodies or the probe may make PspA, but that their PspA molecules may
differ enough from the PspA ofRx 1 that it is not detected by our probe or our
antibodies . This possibility is presently under investigation .
Our past data have indicated that passive administration of two of our four
anti-PspA hybridoma antibodies protected mice from infection with certain
strains ofpneumococci (8) . This finding suggested that immunization with PspA
might be able to elicit protection against pneumococcal infection . In the work
described here we were able to test this supposition by comparing the degree of
protection against the type 3 strain WU2 that was elicited by immunizing xid
mice with normal PspA+ Rx1 pneumococci, and with Rx1 pneumococci that fail
to produce PspA . Our finding indicated that the presence of PspA in Rxl
pneumococci was required for protection, and that of all the surface proteins on
Rx l , PspA was apparently more important than any others at eliciting protection
against strain WU2 .
The function of the PspA protein is unknown . Its absence does not affect
either the growth rate of pneumococci in medium or block their ability to be39 2
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transformed . It does, however, appear to have a detectable effect on the rate of
clearance of D39 pneumococci from the blood during the first few hours after
intravenous injection . As such, it may be one of the factors that contributes to
their virulence .
Summary
PspA is a cell surface protein of Streptococcus pneumoniae that is present on a
number of clinical isolates as well as the nonencapsulated laboratory strain Rx 1 .
In a previous report (8) we have shown that mAbs directed against PspA can
protect mice from at least some of the pneumococcal strains bearing this protein .
In our present report we have produced insertional inactivation mutants that
lack PspA and have used these mutants to demonstrate that PspA can play a role
in pneumococcal virulence and that anti-PspA immunity can lead to protection
against pneumococcal infection .
PspA- mutants were obtained using derivatives of plasmid pVA891 carrying
chromosomal fragments from Rx1 . From one of the mutants, we cloned a 550
by fragment of the pneumococcal gene into pVA891 and transferred this
chimeric plasmid, designated pKSD300, into Escherichia coli . After transforma-
tion ofpKSD300 into Rxl, PspA production is not detected . In colony hybridi-
zation experiments, the 550 by fragment hybridizes specifically to pneumococcal
isolates in a pattern consistent with the hypothesis that the fragment is a portion
of the PspA structural gene that is different from the portions coding for the
antigenic determinants detected by mAbs Xi64 or Xi126. When X-linked im-
munodeficient (xid) CBAJN mice were immunized with wild-type RxI, they were
resistant to challenge with type 3 strain WU2. However, when these mice were
immunized with a PspA- mutant of Rx l , they failed to survive the subsequent
challenge, indicating that immunity to PspA can contribute to the resistance to
pneumococcal infection . Using pKSD300 we insertionally inactivated PspA in
D39, a virulent strain ofS . pneumoniae . When injected intravenously there was a
10-fold greater reduction of the mutant pneumococci in the blood, as compared
to the wild-type D39.
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